Mikael Dolsten M.D., Ph.D.
Net Worth

Last updated:

What is Mikael Dolsten M.D., Ph.D. net worth?

The estimated net worth of Dr. Mikael Dolsten M.D., Ph.D. is at least $51,820,013 as of 7 Nov 2022. He owns shares worth $8,426,886 as insider, has earned $11,893,127 from insider trading and has received compensation worth at least $31,500,000 in Pfizer Inc..

What is the salary of Mikael Dolsten M.D., Ph.D.?

Dr. Mikael Dolsten M.D., Ph.D. salary is $4,500,000 per year as Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical in Pfizer Inc..

How old is Mikael Dolsten M.D., Ph.D.?

Dr. Mikael Dolsten M.D., Ph.D. is 67 years old, born in 1958.

What stocks does Mikael Dolsten M.D., Ph.D. currently own?

As insider, Dr. Mikael Dolsten M.D., Ph.D. owns shares in one company:

Company Title Shares Price per share Total value
Pfizer Inc. (PFE) Chief Scientific Officer and Pres of Worldwide Research, Devel. & Medical 333,342 $25.28 $8,426,886

What does Pfizer Inc. do?

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Mikael Dolsten M.D., Ph.D. insider trading

Pfizer Inc.

Dr. Mikael Dolsten M.D., Ph.D. has made 12 insider trades between 2018-2022, according to the Form 4 filled with the SEC.

The largest trade he's ever made was exercising 199,548 units of PFE stock on 11 Nov 2021. As of 7 Nov 2022 he still owns at least 333,342 units of PFE stock.

Transaction Date Security Shares Price per share Total value Source
Option
Common Stock 50,938 $30.17 $1,536,799
Option
Stock Appreciation Rights 133,430 $38.71 $5,165,075
Option
Common Stock 28,170 $38.71 $1,090,461
Sale
Common Stock 32,015 $49.31 $1,578,660
Sale
Common Stock 18,562 $49.32 $915,478
Sale
Common Stock 2,358 $49.34 $116,344
Sale
Common Stock 2,891 $49.35 $142,671
Sale
Common Stock 7,876 $49.33 $388,523
Sale
Common Stock 200 $49.36 $9,872
Option
Common Stock 40,438 $38.71 $1,565,355
Option
Common Stock 62,022 $27.34 $1,695,681
Option
Stock Appreciation Rights 158,331 $38.71 $6,128,993
Option
Stock Appreciation Rights 152,085 $30.17 $4,588,404
Option
Common Stock 71,187 $30.17 $2,147,712
Option
Common Stock 199,548 $25.28 $5,043,975
Option
Stock Appreciation Rights 127,160 $25.6 $3,255,296
Sale
Common Stock 59,664 $50.31 $3,001,636
Sale
Common Stock 95,353 $37.79 $3,602,913
Sale
Common Stock 95,353 N/A N/A
Sale
Common Stock 49,082 N/A N/A
Sale
Common Stock 49,082 $43.54 $2,137,030
Sale
Common Stock 100,471 N/A N/A
Option
Stock Appreciation Rights 155,172 N/A N/A
Option
Common Stock 106,191 N/A N/A
Option
Common Stock 125,968 N/A N/A
Option
Stock Appreciation Rights 144,928 N/A N/A
Option
Common Stock 181,712 $26.63 $4,838,991
Option
Common Stock 181,712 N/A N/A
Option
Stock Appreciation Rights 185,185 N/A N/A

Pfizer key executives

Pfizer Inc. executives and other stock owners filed with the SEC: